HEADER HYDROLASE 18-AUG-04 1WOF
TITLE CRYSTAL STRUCTURE OF SARS-COV MPRO IN COMPLEX WITH AN INHIBITOR N1
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: 3C-LIKE PROTEINASE;
COMPND 3 CHAIN: A, B;
COMPND 4 EC: 3.4.24.-;
COMPND 5 ENGINEERED: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: SARS CORONAVIRUS;
SOURCE 3 ORGANISM_TAXID: 227859;
SOURCE 4 STRAIN: BJ01;
SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3);
SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008;
SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3);
SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID;
SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PGEX-6P-1
KEYWDS ANTI-PARALLEL B-BARREL, ANTI-PARALLEL A-HELICES, HYDROLASE
EXPDTA X-RAY DIFFRACTION
AUTHOR H.YANG,M.BARTLAM,X.XUE,K.YANG,W.LIANG,Z.RAO
REVDAT 4 30-OCT-24 1WOF 1 REMARK SEQADV LINK
REVDAT 3 24-FEB-09 1WOF 1 VERSN
REVDAT 2 04-OCT-05 1WOF 1 JRNL
REVDAT 1 30-AUG-05 1WOF 0
JRNL AUTH H.YANG,W.XIE,X.XUE,K.YANG,J.MA,W.LIANG,Q.ZHAO,Z.ZHOU,D.PEI,
JRNL AUTH 2 J.ZIEBUHR,R.HILGENFELD,K.Y.YUEN,L.WONG,G.GAO,S.CHEN,Z.CHEN,
JRNL AUTH 3 D.MA,M.BARTLAM,Z.RAO
JRNL TITL DESIGN OF WIDE-SPECTRUM INHIBITORS TARGETING CORONAVIRUS
JRNL TITL 2 MAIN PROTEASES.
JRNL REF PLOS BIOL. V. 3 324 2005
JRNL REFN ISSN 1544-9173
JRNL PMID 16128623
JRNL DOI 10.1371/JOURNAL.PBIO.0030324
REMARK 2
REMARK 2 RESOLUTION. 2.00 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : CNS
REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE-
REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU,
REMARK 3 : READ,RICE,SIMONSON,WARREN
REMARK 3
REMARK 3 REFINEMENT TARGET : ENGH & HUBER
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00
REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL
REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL
REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL
REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL
REMARK 3 NUMBER OF REFLECTIONS : 39635
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : NULL
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING SET) : 0.201
REMARK 3 FREE R VALUE : 0.239
REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL
REMARK 3 FREE R VALUE TEST SET COUNT : 2093
REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : NULL
REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL
REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL
REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL
REMARK 3 BIN R VALUE (WORKING SET) : NULL
REMARK 3 BIN FREE R VALUE : NULL
REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL
REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL
REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 4732
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 88
REMARK 3 SOLVENT ATOMS : 231
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : NULL
REMARK 3 B22 (A**2) : NULL
REMARK 3 B33 (A**2) : NULL
REMARK 3 B12 (A**2) : NULL
REMARK 3 B13 (A**2) : NULL
REMARK 3 B23 (A**2) : NULL
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM SIGMAA (A) : NULL
REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL
REMARK 3
REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM C-V SIGMAA (A) : NULL
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.012
REMARK 3 BOND ANGLES (DEGREES) : 1.890
REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL
REMARK 3 IMPROPER ANGLES (DEGREES) : NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL MODEL : NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA
REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL
REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL
REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL
REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL
REMARK 3
REMARK 3 BULK SOLVENT MODELING.
REMARK 3 METHOD USED : NULL
REMARK 3 KSOL : NULL
REMARK 3 BSOL : NULL
REMARK 3
REMARK 3 NCS MODEL : NULL
REMARK 3
REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT
REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL
REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL
REMARK 3
REMARK 3 PARAMETER FILE 1 : NULL
REMARK 3 TOPOLOGY FILE 1 : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 1WOF COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 20-AUG-04.
REMARK 100 THE DEPOSITION ID IS D_1000023812.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 06-JUL-04
REMARK 200 TEMPERATURE (KELVIN) : 100
REMARK 200 PH : 6.0
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : N
REMARK 200 RADIATION SOURCE : ROTATING ANODE
REMARK 200 BEAMLINE : NULL
REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418
REMARK 200 MONOCHROMATOR : OSMIC MIRROR
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : IMAGE PLATE
REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000
REMARK 200 DATA SCALING SOFTWARE : SCALEPACK
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 42325
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000
REMARK 200 RESOLUTION RANGE LOW (A) : 50.000
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : NULL
REMARK 200 DATA REDUNDANCY : NULL
REMARK 200 R MERGE (I) : NULL
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.01
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.08
REMARK 200 COMPLETENESS FOR SHELL (%) : NULL
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : NULL
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: CNS
REMARK 200 STARTING MODEL: NULL
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 47.70
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.40
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 6000, MES, DMSO, PH 6.0, VAPOR
REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 291K
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X,Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 47.67250
REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC
REMARK 350 SOFTWARE USED: PISA
REMARK 350 TOTAL BURIED SURFACE AREA: 5370 ANGSTROM**2
REMARK 350 SURFACE AREA OF THE COMPLEX: 24940 ANGSTROM**2
REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -11.0 KCAL/MOL
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 GLY A -4
REMARK 465 GLN A 306
REMARK 465 GLY B -4
REMARK 465 PRO B -3
REMARK 465 LEU B -2
REMARK 465 VAL B 303
REMARK 465 THR B 304
REMARK 465 PHE B 305
REMARK 465 GLN B 306
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 SER A 1 -75.92 -42.91
REMARK 500 ASP A 33 -134.25 51.12
REMARK 500 ASP A 34 38.32 -97.72
REMARK 500 HIS A 41 5.48 -66.38
REMARK 500 ASN A 51 68.75 -159.17
REMARK 500 ASN A 84 -121.48 60.77
REMARK 500 TYR A 154 -93.42 79.47
REMARK 500 ASP B 33 -123.96 54.94
REMARK 500 ASN B 84 -123.29 52.90
REMARK 500 HIS B 134 -2.15 77.90
REMARK 500 TYR B 154 -107.04 67.46
REMARK 500 SER B 301 56.75 -157.71
REMARK 500
REMARK 500 REMARK: NULL
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I12 A 1145
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I12 B 2145
REMARK 900
REMARK 900 RELATED ENTRIES
REMARK 900 RELATED ID: 1UJ1 RELATED DB: PDB
REMARK 900 RELATED ID: 1WNO RELATED DB: PDB
REMARK 900 THE SAME PROTEIN COMPLEXED WITH AN INHIBITOR I2
DBREF 1WOF A 1 306 UNP P59641 R1AB_CVHSA 3241 3546
DBREF 1WOF B 1 306 UNP P59641 R1AB_CVHSA 3241 3546
SEQADV 1WOF GLY A -4 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF PRO A -3 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF LEU A -2 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF GLY A -1 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF SER A 0 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF GLY B -4 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF PRO B -3 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF LEU B -2 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF GLY B -1 UNP P59641 CLONING ARTIFACT
SEQADV 1WOF SER B 0 UNP P59641 CLONING ARTIFACT
SEQRES 1 A 311 GLY PRO LEU GLY SER SER GLY PHE ARG LYS MET ALA PHE
SEQRES 2 A 311 PRO SER GLY LYS VAL GLU GLY CYS MET VAL GLN VAL THR
SEQRES 3 A 311 CYS GLY THR THR THR LEU ASN GLY LEU TRP LEU ASP ASP
SEQRES 4 A 311 THR VAL TYR CYS PRO ARG HIS VAL ILE CYS THR ALA GLU
SEQRES 5 A 311 ASP MET LEU ASN PRO ASN TYR GLU ASP LEU LEU ILE ARG
SEQRES 6 A 311 LYS SER ASN HIS SER PHE LEU VAL GLN ALA GLY ASN VAL
SEQRES 7 A 311 GLN LEU ARG VAL ILE GLY HIS SER MET GLN ASN CYS LEU
SEQRES 8 A 311 LEU ARG LEU LYS VAL ASP THR SER ASN PRO LYS THR PRO
SEQRES 9 A 311 LYS TYR LYS PHE VAL ARG ILE GLN PRO GLY GLN THR PHE
SEQRES 10 A 311 SER VAL LEU ALA CYS TYR ASN GLY SER PRO SER GLY VAL
SEQRES 11 A 311 TYR GLN CYS ALA MET ARG PRO ASN HIS THR ILE LYS GLY
SEQRES 12 A 311 SER PHE LEU ASN GLY SER CYS GLY SER VAL GLY PHE ASN
SEQRES 13 A 311 ILE ASP TYR ASP CYS VAL SER PHE CYS TYR MET HIS HIS
SEQRES 14 A 311 MET GLU LEU PRO THR GLY VAL HIS ALA GLY THR ASP LEU
SEQRES 15 A 311 GLU GLY LYS PHE TYR GLY PRO PHE VAL ASP ARG GLN THR
SEQRES 16 A 311 ALA GLN ALA ALA GLY THR ASP THR THR ILE THR LEU ASN
SEQRES 17 A 311 VAL LEU ALA TRP LEU TYR ALA ALA VAL ILE ASN GLY ASP
SEQRES 18 A 311 ARG TRP PHE LEU ASN ARG PHE THR THR THR LEU ASN ASP
SEQRES 19 A 311 PHE ASN LEU VAL ALA MET LYS TYR ASN TYR GLU PRO LEU
SEQRES 20 A 311 THR GLN ASP HIS VAL ASP ILE LEU GLY PRO LEU SER ALA
SEQRES 21 A 311 GLN THR GLY ILE ALA VAL LEU ASP MET CYS ALA ALA LEU
SEQRES 22 A 311 LYS GLU LEU LEU GLN ASN GLY MET ASN GLY ARG THR ILE
SEQRES 23 A 311 LEU GLY SER THR ILE LEU GLU ASP GLU PHE THR PRO PHE
SEQRES 24 A 311 ASP VAL VAL ARG GLN CYS SER GLY VAL THR PHE GLN
SEQRES 1 B 311 GLY PRO LEU GLY SER SER GLY PHE ARG LYS MET ALA PHE
SEQRES 2 B 311 PRO SER GLY LYS VAL GLU GLY CYS MET VAL GLN VAL THR
SEQRES 3 B 311 CYS GLY THR THR THR LEU ASN GLY LEU TRP LEU ASP ASP
SEQRES 4 B 311 THR VAL TYR CYS PRO ARG HIS VAL ILE CYS THR ALA GLU
SEQRES 5 B 311 ASP MET LEU ASN PRO ASN TYR GLU ASP LEU LEU ILE ARG
SEQRES 6 B 311 LYS SER ASN HIS SER PHE LEU VAL GLN ALA GLY ASN VAL
SEQRES 7 B 311 GLN LEU ARG VAL ILE GLY HIS SER MET GLN ASN CYS LEU
SEQRES 8 B 311 LEU ARG LEU LYS VAL ASP THR SER ASN PRO LYS THR PRO
SEQRES 9 B 311 LYS TYR LYS PHE VAL ARG ILE GLN PRO GLY GLN THR PHE
SEQRES 10 B 311 SER VAL LEU ALA CYS TYR ASN GLY SER PRO SER GLY VAL
SEQRES 11 B 311 TYR GLN CYS ALA MET ARG PRO ASN HIS THR ILE LYS GLY
SEQRES 12 B 311 SER PHE LEU ASN GLY SER CYS GLY SER VAL GLY PHE ASN
SEQRES 13 B 311 ILE ASP TYR ASP CYS VAL SER PHE CYS TYR MET HIS HIS
SEQRES 14 B 311 MET GLU LEU PRO THR GLY VAL HIS ALA GLY THR ASP LEU
SEQRES 15 B 311 GLU GLY LYS PHE TYR GLY PRO PHE VAL ASP ARG GLN THR
SEQRES 16 B 311 ALA GLN ALA ALA GLY THR ASP THR THR ILE THR LEU ASN
SEQRES 17 B 311 VAL LEU ALA TRP LEU TYR ALA ALA VAL ILE ASN GLY ASP
SEQRES 18 B 311 ARG TRP PHE LEU ASN ARG PHE THR THR THR LEU ASN ASP
SEQRES 19 B 311 PHE ASN LEU VAL ALA MET LYS TYR ASN TYR GLU PRO LEU
SEQRES 20 B 311 THR GLN ASP HIS VAL ASP ILE LEU GLY PRO LEU SER ALA
SEQRES 21 B 311 GLN THR GLY ILE ALA VAL LEU ASP MET CYS ALA ALA LEU
SEQRES 22 B 311 LYS GLU LEU LEU GLN ASN GLY MET ASN GLY ARG THR ILE
SEQRES 23 B 311 LEU GLY SER THR ILE LEU GLU ASP GLU PHE THR PRO PHE
SEQRES 24 B 311 ASP VAL VAL ARG GLN CYS SER GLY VAL THR PHE GLN
HET I12 A1145 44
HET I12 B2145 44
HETNAM I12 N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]-L-ALANYL-L-VALYL-
HETNAM 2 I12 N~1~-((1S)-4-ETHOXY-4-OXO-1-{[(3S)-2-OXOPYRROLIDIN-3-
HETNAM 3 I12 YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE
HETSYN I12 (E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-
HETSYN 2 I12 METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-
HETSYN 3 I12 BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-
HETSYN 4 I12 PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER
FORMUL 3 I12 2(C30 H46 N6 O8)
FORMUL 5 HOH *231(H2 O)
HELIX 1 1 SER A 10 GLY A 15 1 6
HELIX 2 2 HIS A 41 CYS A 44 5 4
HELIX 3 3 THR A 45 LEU A 50 5 6
HELIX 4 4 ASN A 53 ARG A 60 1 8
HELIX 5 5 SER A 62 HIS A 64 5 3
HELIX 6 6 ILE A 200 ASN A 214 1 15
HELIX 7 7 THR A 226 MET A 235 1 10
HELIX 8 8 LYS A 236 ASN A 238 5 3
HELIX 9 9 THR A 243 LEU A 250 1 8
HELIX 10 10 LEU A 250 GLY A 258 1 9
HELIX 11 11 ALA A 260 GLY A 275 1 16
HELIX 12 12 THR A 292 GLY A 302 1 11
HELIX 13 13 SER B 10 GLY B 15 1 6
HELIX 14 14 HIS B 41 CYS B 44 5 4
HELIX 15 15 ASN B 53 ARG B 60 1 8
HELIX 16 16 SER B 62 HIS B 64 5 3
HELIX 17 17 ILE B 200 ASN B 214 1 15
HELIX 18 18 THR B 226 MET B 235 1 10
HELIX 19 19 LYS B 236 ASN B 238 5 3
HELIX 20 20 THR B 243 LEU B 250 1 8
HELIX 21 21 LEU B 250 GLY B 258 1 9
HELIX 22 22 ALA B 260 GLY B 275 1 16
HELIX 23 23 THR B 292 SER B 301 1 10
SHEET 1 A 7 VAL A 73 LEU A 75 0
SHEET 2 A 7 PHE A 66 ALA A 70 -1 N VAL A 68 O LEU A 75
SHEET 3 A 7 MET A 17 CYS A 22 -1 N THR A 21 O LEU A 67
SHEET 4 A 7 THR A 25 LEU A 32 -1 O LEU A 27 N VAL A 20
SHEET 5 A 7 THR A 35 PRO A 39 -1 O TYR A 37 N LEU A 30
SHEET 6 A 7 LEU A 86 VAL A 91 -1 O LEU A 89 N VAL A 36
SHEET 7 A 7 VAL A 77 GLN A 83 -1 N SER A 81 O ARG A 88
SHEET 1 B 5 TYR A 101 PHE A 103 0
SHEET 2 B 5 CYS A 156 GLU A 166 1 O PHE A 159 N LYS A 102
SHEET 3 B 5 VAL A 148 ASP A 153 -1 N ASP A 153 O CYS A 156
SHEET 4 B 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150
SHEET 5 B 5 SER A 121 ALA A 129 -1 O SER A 123 N ALA A 116
SHEET 1 C 3 TYR A 101 PHE A 103 0
SHEET 2 C 3 CYS A 156 GLU A 166 1 O PHE A 159 N LYS A 102
SHEET 3 C 3 HIS A 172 THR A 175 -1 O ALA A 173 N MET A 165
SHEET 1 D 7 VAL B 73 LEU B 75 0
SHEET 2 D 7 PHE B 66 ALA B 70 -1 N VAL B 68 O LEU B 75
SHEET 3 D 7 MET B 17 CYS B 22 -1 N THR B 21 O LEU B 67
SHEET 4 D 7 THR B 25 LEU B 32 -1 O LEU B 27 N VAL B 20
SHEET 5 D 7 THR B 35 PRO B 39 -1 O TYR B 37 N LEU B 30
SHEET 6 D 7 LEU B 86 VAL B 91 -1 O LEU B 89 N VAL B 36
SHEET 7 D 7 VAL B 77 GLN B 83 -1 N SER B 81 O ARG B 88
SHEET 1 E 5 LYS B 100 PHE B 103 0
SHEET 2 E 5 CYS B 156 GLU B 166 1 O VAL B 157 N LYS B 100
SHEET 3 E 5 VAL B 148 ASP B 153 -1 N ASN B 151 O SER B 158
SHEET 4 E 5 THR B 111 TYR B 118 -1 N SER B 113 O PHE B 150
SHEET 5 E 5 SER B 121 ALA B 129 -1 O TYR B 126 N VAL B 114
SHEET 1 F 3 LYS B 100 PHE B 103 0
SHEET 2 F 3 CYS B 156 GLU B 166 1 O VAL B 157 N LYS B 100
SHEET 3 F 3 HIS B 172 THR B 175 -1 O ALA B 173 N MET B 165
LINK SG CYS A 145 C21 I12 A1145 1555 1555 1.81
LINK SG CYS B 145 C21 I12 B2145 1555 1555 1.80
SITE 1 AC1 22 THR A 25 THR A 26 HIS A 41 MET A 49
SITE 2 AC1 22 PHE A 140 ASN A 142 GLY A 143 SER A 144
SITE 3 AC1 22 CYS A 145 HIS A 163 HIS A 164 MET A 165
SITE 4 AC1 22 GLU A 166 HIS A 172 ASP A 187 ARG A 188
SITE 5 AC1 22 GLN A 189 THR A 190 ALA A 191 GLN A 192
SITE 6 AC1 22 HOH A1257 HOH A1258
SITE 1 AC2 18 THR B 26 HIS B 41 PHE B 140 ASN B 142
SITE 2 AC2 18 GLY B 143 SER B 144 CYS B 145 HIS B 163
SITE 3 AC2 18 HIS B 164 MET B 165 GLU B 166 PRO B 168
SITE 4 AC2 18 HIS B 172 ASP B 187 GLN B 189 THR B 190
SITE 5 AC2 18 ALA B 191 HOH B2259
CRYST1 51.683 95.345 67.530 90.00 103.57 90.00 P 1 21 1 4
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.019349 0.000000 0.004672 0.00000
SCALE2 0.000000 0.010488 0.000000 0.00000
SCALE3 0.000000 0.000000 0.015234 0.00000